MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas B. Powles, Joseph P. Eder, Gregg Daniel Fine et al. · Nature · 2014
Cited by 2,381 works. doi:10.1038/nature13904
Authors
- Thomas B. Powles
- Joseph P. Eder
- Gregg Daniel Fine
- Fadi S. Braiteh
- Yohann Loriot
- Cristina Cruz
- Joaquim Bellmunt B
- Howard A. Burris
- Daniel Peter Petrylak
- Siew-leng Melinda Teng
- Zachary S. Boyd
- Priti S. Hegde
- Daniel S. Chen
- Nicholas J. Vogelzang
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Cloning of a new cytokine that induces IFN-γ production by T cells
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Mutational landscape and significance across 12 major cancer types
- Comprehensive molecular characterization of urothelial bladder carcinoma